SCHEDULE: OrbiMed Updates Stake in Prelude Therapeutics

OrbiMed Advisors reports a change in beneficial ownership of Prelude Therapeutics following a recent public offering.

Summary

• OrbiMed Advisors and affiliated entities filed an amendment to their Schedule 13D regarding their holdings in Prelude Therapeutics Inc.
• The filing follows an underwritten public offering completed by the issuer on April 21, 2026.
• The offering included 18,018,014 shares at $4.44 per share and pre-funded warrants.
• OrbiMed entities participated in the offering, purchasing 1,689,189 shares via OPI VI and 1,126,126 shares via Genesis.
• Due to the increase in total outstanding shares from the offering, the reporting persons' percentage ownership decreased by more than 1%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting a change in ownership percentage due to a public offering, rather than a change in investment thesis.

Positives

• OrbiMed continues to demonstrate support for the issuer by participating in the recent public offering.
• The issuer successfully completed an underwritten public offering, strengthening its capital position.

Negatives

• The reporting persons' total percentage ownership in the issuer decreased due to the dilution from the new share issuance.

Risks

• The issuer's business, financial condition, and market prospects remain subject to general economic and industry conditions.
• Future investment decisions by the reporting persons are subject to market conditions and other investment opportunities.
• The reporting persons may dispose of some or all of their shares in the future depending on market factors.

Future Outlook

The reporting persons intend to review their investment in the issuer periodically based on business performance, financial condition, and market conditions, and may acquire or dispose of shares as they deem appropriate.

Management Comments

• The reporting persons have not formulated any plans or proposals regarding extraordinary corporate transactions, changes to the board, or material changes to the issuer's capitalization or business structure.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional participation in biotech follow-on offerings, where major venture capital backers often maintain their pro-rata interest or provide support during capital raises to ensure the issuer remains well-funded for clinical development.

Comparison to Industry Standards

• The participation of OrbiMed in the offering is consistent with typical behavior for specialized life sciences investment firms supporting portfolio companies.
• The use of Lock-Up Agreements for directors and officers is standard practice in underwritten public offerings to stabilize the share price post-issuance.

Corporate Governance

Related Party Transactions

• David P. Bonita, a member of OrbiMed Advisors, serves on the Board of Directors of the issuer.

Stakeholder Impact

• Existing shareholders experienced dilution due to the issuance of new shares in the public offering.
• The issuer improved its liquidity position through the capital raise.

Next Steps

• Expiration of the 60-day lock-up period for directors and officers.
• Ongoing monitoring of the issuer's business and market performance by the reporting persons.

Key Dates

Keywords

Prelude Therapeutics, OrbiMed, Schedule 13D, Biotech, Equity Offering, Beneficial Ownership